Epidermal growth factor receptor (EGFR) gene promoter methylation and cetuximab treatment in colorectal cancer patients

British Journal of Cancer

Volumn 104, Issue 11, 2011, Pages 1786-1790

  Scartozzi, M ^a   Bearzi, I ^a   Mandolesi, A ^a   Giampieri, R ^a   Faloppi, L ^a   Galizia, E ^b   Loupakis, F ^c   Zaniboni, A ^d   Zorzi, F ^d   Biscotti, T ^a   Labianca, R ^e   Falcone, A ^c   Cascinu, S ^a  

^a UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^b Oncologia Medica   (Italy)

^c UNIVERSITY OF PISA   (Italy)

^d Fondazione Poliambulanza   (Italy)

^e OSPEDALI RIUNITI   (Italy)

Author keywords

cetuximab; colorectal cancer; EGFR promoter methylation

Indexed keywords

CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; FLUOROURACIL; FOLINIC ACID; IRINOTECAN;

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER SURVIVAL; COLORECTAL CANCER; DNA METHYLATION; DRUG RESPONSE; EGFR GENE; FEMALE; GENE; HUMAN; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROMOTER REGION; SURVIVAL TIME;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CAMPTOTHECIN; COLORECTAL NEOPLASMS; DISEASE PROGRESSION; DNA METHYLATION; FEMALE; GENES, ERBB-1; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PROMOTER REGIONS, GENETIC; TREATMENT OUTCOME;

EID: 79957599577     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2011.161     Document Type: Article

References (28)

1. Atkins D, Reiffen KA, Tegtmeier CL, Winther H, Bonato MS, Störkel S (2004) Immunohistochemical detection of EGFR in paraffin-embedded tumor tissues: variation in staining intensity due to choice of fixative and storage time of tissue sections. Histochem Cytochem 52: 893-901 (Pubitemid 38857154)
2. Benvenuti S, Sartore-Bianchi A, Di Nicolantonio F, Zanon C, Moroni M, Veronese S, Siena S, Bardelli A (2007) Oncogenetic activation of RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies. Cancer Res 67: 2643-2648 (Pubitemid 46548951)
3. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, Bets D, Mueser M, Harstrick A, Verslype C, Chau I, Van Cutsem E (2004) Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351: 337-345 (Pubitemid 38944402)
4. Devereux TR, Horikawa I, Anna CH, Annab LA, Afshari CA, Barrett JC (1999) DNA methylation analysis of the promoter region of the human telomerase reverse transcriptase (hTERT) gene. Cancer Res 59: 6087-6090 (Pubitemid 30035625)
5. Di Fiore F, Blanchard F, Charbonnier F, Le Pessot F, Lamy A, Galais MP, Bastit L, Killian A, Sesboüé R, Tuech JJ, Queuniet AM, Paillot B, Sabourin JC, Michot F, Michel P, Frebourg T (2007) Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by cetuximab plus chemotherapy. Br J Cancer 96: 1166-1169 (Pubitemid 46625066)
6. Di Nicolantonio F, Martini M, Molinari F, Sartore-Bianchi A, Arena S, Saletti P, De Dosso S, Mazzucchelli L, Frattini M, Siena S, Bardelli A (2008) Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol 26: 5705-5712
7. Herman JG, Baylin SB (2003) Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 349: 2042-2054 (Pubitemid 37448928)
8. Herman JG, Graff JR, Myöhänen S, Nelkin BD, Baylin SB (1996) Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA 93: 9821-9826 (Pubitemid 26296693)
9. Jones PA, Baylin SB (2002) The fundamental role of epigenetic events in cancer. Nat Rev Genet 3: 415-428 (Pubitemid 34587077)
10. Jonker DJ, O'Callaghan CJ, Karapetis CS, Zalcberg JR, Tu D, Au HJ, Berry SR, Krahn M, Price T, Simes RJ, Tebbutt NC, Van Hazel G, Wierzbicki R, Langer C, Moore MJ (2007) Cetuximab for the treatment of colorectal cancer. J Clin Oncol 357: 2040-2047
11. Karpf AR, Jones DA (2002) Reactivating the expression of methylation silenced genes in human cancer. Oncogene 21: 5496-5503 (Pubitemid 34983484)
12. Lievre A, Bachet JB, Boige V, Cayre A, Le Corre D, Buc E, Ychou M, Bouché O, Landi B, Louvet C, André T, Bibeau F, Diebold MD, Rougier P, Ducreux M, Tomasic G, Emile JF, Penault-Llorca F, Laurent-Puig P (2008) Kras mutation as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol 28: 374-379 (Pubitemid 351171687)
13. Loupakis F, Pollina L, Stasi I, Ruzzo A, Scartozzi M, Santini D, Masi G, Graziano F, Cremolini C, Rulli E, Canestrari E, Funel N, Schiavon G, Petrini I, Magnani M, Tonini G, Campani D, Floriani I, Cascinu S, Falcone A (2009) PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer. J Clin Oncol 27: 2622-2629
14. Merlino GT, Ishii S, Whang-Peng J, Knutsen T, Xu YH, Clark AJ, Stratton RH, Wilson RK, Ma DP, Roe BA, Hunts JH, Shimizu N, Pastan I (1985) Structure and localization of genes encoding aberrant and normal epidermal growth factor receptor RNAs from A431 human carcinoma cells. Mol Cell Biol 5: 1722-1734 (Pubitemid 15061730)
15. Montero AJ, Marcela D́ýaz-Montero C, Mao L, Youssef EM, Estecio M, Shen L, Issa JP (2006) Epigenetic inactivation of EGFR by CpG island hypermethylation in cancer. Cancer Biol Ther 5: 1494-1501
16. Moroni M, Veronese S, Benvenuti S, Marrapese G, Sartore-Bianchi A, Di Nicolantonio F, Gambacorta M, Siena S, Bardelli A (2005) Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to anti EGFR treatment in colorectal cancer: a cohort study. Lancet Oncol 6: 279-286 (Pubitemid 40590264)
17. Nagothu KK, Rishi AK, Jaszewski R, Kucuk O, Majumdar AP (2004) Folic acid- mediated inhibition of serum-induced activation of EGFR promoter in colon cancer cells. Am J Physiol Gastrointestinal Liver Physiol 287: 541-546
18. Ng K, Zhu AX (2008) Targeting the epidermal growth factor receptor in metastatic colorectal cancer. Crit Rev Oncol/Hematol 65: 8-20 (Pubitemid 350216479)
19. Perrone F, Lampis A, Orsenigo M, Di Bartolomeo M, Gevorgyan A, Losa M, Frattini M, Riva C, Andreola S, Bajetta E, Bertario L, Leo E, Pierotti MA, Pilotti S (2009) PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients. Ann Oncol 20: 84-90
20. Santini V, Kantarjian HM, Issa JP (2001) Changes in DNA methylation in neoplasia: pathophysiology and therapeutic implications. Ann Intern Med 134: 573-586 (Pubitemid 32245319)
21. Scartozzi M, Bearzi I, Berardi R, Mandolesi A, Fabris G, Cascinu S (2004) Epidermal growth factor receptor (EGFR) status in primary colorectal tumors does not correlate with EGFR expression in related metastatic sites: implications for treatment with EGFR-targeted monoclonal antibodies. J Clin Oncol 22: 4772-4778
22. Scartozzi M, Bearzi I, Pierantoni C, Mandolesi A, Loupakis F, Zaniboni A, Catalano V, Quadri A, Zorzi F, Berardi R, Biscotti T, Labianca R, Falcone A, Cascinu S (2007) Nuclear factor-kB tumor expression predicts response and survival in irinotecan-refractory metastatic colorectal cancer treated with cetuximab-irinotecan therapy. J Clin Oncol 25: 3930-3935 (Pubitemid 47477270)
23. Scartozzi M, Bearzi I, Mandolesi A, Pierantoni C, Loupakis F, Zaniboni A, Negri F, Quadri A, Zorzi F, Galizia E, Berardi R, Biscotti T, Labianca R, Masi G, Falcone A, Cascinu S (2009) Epidermal growth factor receptor (EGFR) gene copy number (GCN) correlates with clinical activity of irinotecan-cetuximab in K-RAS wild-type colorectal cancer: a fluorescence in situ (FISH) and chromogenic in situ hybridization (CISH) analysis. BMC 9: 303-310
24. Scartozzi M, Bearzi I, Mandolesi A, Galizia E, Pierantoni C, Loupakis F, Berardi R, Zaniboni A, Quadri A, Zorzi F, Biagetti S, Loretelli C, Biscotti T, Labianca R, Masi G, Falcone A, Cascinu S (2009) Epidermal growth factor receptor gene promoter methylation in primary colorectal tumors and corresponding metastatic sites: a new perspective for an 'old' therapeutic target. Anal Quant Cytol Histol 31: 417-423
25. Vallböhmer D, Zhang W, Gordon M, Yang DY, Yun J, Press OA, Rhodes KE, Sherrod AE, Iqbal S, Danenberg KD, Groshen S, Lenz HJ (2005) Molecular determinants of cetuximab efficacy. J Clin Oncol 23: 3536-3544
26. Van Cutsem E, Kohne CH, Hitre E, Zaluski J, Chang Chien CR, Makhson A, D'Haens G, Pintér T, Lim R, Bodoky G, Roh JK, Folprecht G, Ruff P, Stroh C, Tejpar S, Schlichting M, Nippgen J, Rougier P (2009) Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 360: 1408-1417
27. Van Cutsem E, Peeters M, Siena S, Humblet Y, Hendlisz A, Neyns B, Canon JL, Van Laethem JL, Maurel J, Richardson G, Wolf M, Amado RG (2007) Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 25: 1658-1664 (Pubitemid 46797944)
28. Xu YH, Richert N, Ito S, Merlino GT, Pastan I (1984) Characterization of epidermal growth factor receptor gene expression in malignant and normal human cell lines. Proc Natl Acad Sci USA 81: 7308-7312 (Pubitemid 15196172)